null
SMILES: C[C@H](O)CNCc1cnc2c(Nc3cccc(c3C)-c3cccc(-c4nc5cc(CN6CC[C@H](C6)C(O)=O)cc(C#N)c5o4)c3C)nc(C)nc2c1
InChI Key: InChIKey=NOJRWPNNJBEHCJ-RBISFHTESA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167] (Homo sapiens (Human)) | BDBM446457 ((R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxyprop...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Incyte Corporation US Patent | Assay Description The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in... | US Patent US10669271 (2020) BindingDB Entry DOI: 10.7270/Q2MG7SJC | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Programmed cell death 1 ligand 1 [19-238]/protein 1 [25-167] (Homo sapiens (Human)) | BDBM446457 ((R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxyprop...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description The assays were conducted in a standard black 384-well polystyrene plate with a final volume of 20 μL. Inhibitors were first serially diluted in... | Citation and Details BindingDB Entry DOI: 10.7270/Q2VT1W8C | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Nuclear factor NF-kappa-B p105 subunit (Homo sapiens (Human)) | BDBM446457 ((R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxyprop...) | PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 55 | n/a | n/a | n/a | n/a |
Incyte Corporation US Patent | Assay Description PD-L1 aAPC/CHO-Klcells (Promega) were maintained in F-12 medium with addition of 10% FBS, 200 μg/ml Hygromycin B, 250 μg/ml Geneticin (G418... | US Patent US10669271 (2020) BindingDB Entry DOI: 10.7270/Q2MG7SJC | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein phosphatase non-receptor type 11 (Homo sapiens (Human)) | BDBM446457 ((R)-1-((7-cyano-2-(3′-(7-(((S)-2-hydroxyprop...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
Incyte Corporation US Patent | Assay Description U2OS/PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium with addition of 10% FBS, 0.25 μg/ml Puromycin. After removing... | US Patent US10669271 (2020) BindingDB Entry DOI: 10.7270/Q2MG7SJC | |||||||||||
More data for this Ligand-Target Pair |